DaunoXome

Active Ingredient(s): Daunorubicin Liposomal
FDA Approved: * April 8, 1996
Pharm Company: * GILEAD
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

DaunoXome Overview

Daunorubicin, also known as daunomycin, is a chemotherapy medication used to treat cancer.[1] Specifically it is used for acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and Kaposi's sarcoma.[1] It is used by injection into a vein.[1] A liposomal formulation known as liposomal daunorubicin also exists.[1] Common side effects include hair loss, vomiting, bone marrow suppression, ...

Read more DaunoXome Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Daunorubicin

Recent DaunoXome Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for DaunoXome: (1 result)

Sorted by National Drug Code

• 10885-001 Daunoxome 2 mg/ml Intravenous Injection, Lipid Complex by Galen Us Inc

Other drugs which contain Daunorubicin Liposomal or a similar ingredient: (1 result)

• DAUNORUBICIN LIPOSOMAL